L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 5.04 NOK 0.8%
Market Cap: 344m NOK

EV/FCFF
Enterprise Value to FCFF

-3.7
Current
-5.5
Median
3.3
Industry
Higher than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-3.7
=
Enterprise Value
302.6m NOK
/
FCFF
-81.5m NOK
 
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average EV/FCFF: 23.5
Negative Multiple: -3.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -229 813.7
US
Abbvie Inc
NYSE:ABBV
23.8
US
Amgen Inc
NASDAQ:AMGN
20.4
US
Gilead Sciences Inc
NASDAQ:GILD
15
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -119.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -488.1
AU
CSL Ltd
ASX:CSL
44.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -59
NL
argenx SE
XBRU:ARGX
Negative Multiple: -99

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A